Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2025 that were previously approved by the Compensation ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

BofA lowered the firm’s price target on Sarepta (SRPT) to $179 from $210 and keeps a Buy rating on the shares. Following the news of the ...

The S&P 500 Index ($SPX) (SPY) today is down -1.54%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -1.00%, and the ...

Novavax (NVAX), and BioNTech (BNTX) (BTNX), and gene therapy developers, including Sarepta (SRPT), Solid Biosciences (SLDB), Taysha Gene Therapies (TSHA), Capricor Therapeutics (CAPR), and Crispr ...

Shares of some U.S. biotechnology companies including Moderna (MRNA) plunged on Monday after reports that the top vaccine official at the U.S.

RBC Capital analyst Brian Abrahams downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161. The ...

RBC Capital downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161.Don't Miss Our End of ...

Mizuho Securities analyst Uy Ear maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

Avidity Biosciences, Inc.'s innovative AOC platform and promising clinical programs make it a high-risk, high-reward ...